Chiranth Prakash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chiranth Prakash has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Dominik Spitz
2 shared publicationsJost Wiggering
2 shared publications- Maximilian H. Ulbrich
Department of Medicine IV, University Freiburg Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
2 shared publications - Ronen Schneider
Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts
2 shared publications - Tobias Hermle
Renal Division, Department of Medicine, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany
2 shared publications - Akash Sabarwal
Boston Children’s Hospital 1 Division of Nephrology Boston, Massachusetts
1 shared publication
Latest Publications
- 16 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF14
Inhibition of PLK1 Helps Restrict c-Met–Induced Growth and Therapeutic Resistance of Renal Cancer Cells
Acquired therapeutic resistance is a major problem in the treatment of advanced renal cell carcinoma (RCC). The receptor tyrosine kinase (RTK) c-Met is hyperactive in RCC and plays a major role in the survival of tumor cells during therapy-induced oxidative stress. Although the c-Met/RTK inhibitor cabozantinib (cabo) has demonstrated efficacy in the treatment of RCC, therapeutic resistance significantly restricts its effectiveness. Thus, new target molecules and combination therapies need to be explored. Among several cell-cycle regulators, Polo-like kinase 1 (PLK1), which is overexpressed in RCC, can play a vital role in cancer progression. In this study, for the first time, we show that the activation of c-Met markedly promotes renal cancer cell growth and proliferation through PLK1. We found that a novel combination treatment with cabo and a PLK1 inhibitor (onvansertib) induces dual-phase cell-cycle arrest at both G1 and G2–M checkpoints and impairs RCC cell migration. It induces tumor cell apoptosis by downregulating the antioxidant transcription factor/cytoprotective molecule Nrf2/heme oxygenase-1 and inducing oxidative stress. Our results also showed that onvansertib can downregulate ATP-binding cassette transporters that are involved in drug resistance, and it resensitizes cabo-resistant RCC cells to apoptotic cell death. We further confirmed the effectiveness of the combination treatment through 3D spheroid culture as well as tumor xenograft models of RCC. Following combination treatment, there was increased drug-induced cytotoxicity and markedly reduced tumor growth in vivo. Together, our preclinical study identifies that cabo + onvansertib is an effective combination treatment to overcome c-Met–induced therapeutic resistance in RCC with translational potential.
- 16 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF14
Inhibition of PLK1 Helps Restrict c-Met–Induced Growth and Therapeutic Resistance of Renal Cancer Cells
Acquired therapeutic resistance is a major problem in the treatment of advanced renal cell carcinoma (RCC). The receptor tyrosine kinase (RTK) c-Met is hyperactive in RCC and plays a major role in the survival of tumor cells during therapy-induced oxidative stress. Although the c-Met/RTK inhibitor cabozantinib (cabo) has demonstrated efficacy in the treatment of RCC, therapeutic resistance significantly restricts its effectiveness. Thus, new target molecules and combination therapies need to be explored. Among several cell-cycle regulators, Polo-like kinase 1 (PLK1), which is overexpressed in RCC, can play a vital role in cancer progression. In this study, for the first time, we show that the activation of c-Met markedly promotes renal cancer cell growth and proliferation through PLK1. We found that a novel combination treatment with cabo and a PLK1 inhibitor (onvansertib) induces dual-phase cell-cycle arrest at both G1 and G2–M checkpoints and impairs RCC cell migration. It induces tumor cell apoptosis by downregulating the antioxidant transcription factor/cytoprotective molecule Nrf2/heme oxygenase-1 and inducing oxidative stress. Our results also showed that onvansertib can downregulate ATP-binding cassette transporters that are involved in drug resistance, and it resensitizes cabo-resistant RCC cells to apoptotic cell death. We further confirmed the effectiveness of the combination treatment through 3D spheroid culture as well as tumor xenograft models of RCC. Following combination treatment, there was increased drug-induced cytotoxicity and markedly reduced tumor growth in vivo. Together, our preclinical study identifies that cabo + onvansertib is an effective combination treatment to overcome c-Met–induced therapeutic resistance in RCC with translational potential.
- 1 August 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (8)
Cover Image
- 1 August 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (8)
Cover Image
- 27 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (8) , 1505-1519
A Drug Screening Platform for Podocytopathies in Drosophila Nephrocytes
Key Points: We developed a fast assay testing Drosophila nephrocyte function, suitable for whole-animal drug screening in these podocyte-like cells. Rac1 overexpression disrupted nephrocyte slit diaphragm architecture, providing a screening background relevant to podocyte (patho)biology. A pilot screen using the novel podocytopathy platform identified that zacopride restores slit diaphragms despite excess of Rac1. Background: The complex cellular architecture of the glomerular filtration barrier is not recapitulated in vitro , representing a major obstacle for drug screening. This contributes significantly to a therapeutic gap for the heterogeneous diseases affecting the podocyte. Phenotypic drug screening using whole organisms is inherently slow but can reveal entirely unexpected therapies that are unattainable by conventional screening. The Drosophila nephrocyte features a molecularly conserved filtration barrier, suitable for whole-animal screening in podocytopathies. Methods: We generated transgenic Drosophila expressing a secretable variant of green fluorescent protein as a genetically encoded tracer for rapid analysis of nephrocyte function. Animals were exposed to drugs in liquid food before recording nephrocyte fluorescence intensity. The slit diaphragm architecture was investigated using immunofluorescence and subsequent automated quantification. Results: The genetically encoded tracer, combined with fast detection through enhanced widefield fluorescence microscopy, provided a faster but reliable screening assay for nephrocyte function compared with the established approach using FITC-albumin ex vivo . Rac1 is a key regulator of the actin cytoskeleton, involved in maintaining podocyte structure and function. In nephrocytes, overexpression of Rac1 resulted in mislocalization of slit diaphragm proteins and deeper membrane invaginations. Since nephrocyte function was further decreased as detected by the novel assay, we used this screening background relevant to podocyte biology for a pilot screen of 100 drugs. We identified significant improvement of nephrocyte function for zacopride, a respective agonist or antagonist of serotonin receptors, which restored the slit diaphragm architecture despite overexpression of Rac1 . The mechanism of action of zacopride appeared independent from the orthologs of the mammalian target proteins or direct Rac1 inhibition, suggesting a pleiotropic target. This hit from the pilot screen illustrates the potential of phenotypic drug screening to reveal unexpected therapeutic options. Conclusions: We present a proof of concept for whole-animal drug screening using podocyte-like Drosophila nephrocytes.
- 27 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (8) , 1505-1519
A Drug Screening Platform for Podocytopathies in Drosophila Nephrocytes
Key Points: We developed a fast assay testing Drosophila nephrocyte function, suitable for whole-animal drug screening in these podocyte-like cells. Rac1 overexpression disrupted nephrocyte slit diaphragm architecture, providing a screening background relevant to podocyte (patho)biology. A pilot screen using the novel podocytopathy platform identified that zacopride restores slit diaphragms despite excess of Rac1. Background: The complex cellular architecture of the glomerular filtration barrier is not recapitulated in vitro , representing a major obstacle for drug screening. This contributes significantly to a therapeutic gap for the heterogeneous diseases affecting the podocyte. Phenotypic drug screening using whole organisms is inherently slow but can reveal entirely unexpected therapies that are unattainable by conventional screening. The Drosophila nephrocyte features a molecularly conserved filtration barrier, suitable for whole-animal screening in podocytopathies. Methods: We generated transgenic Drosophila expressing a secretable variant of green fluorescent protein as a genetically encoded tracer for rapid analysis of nephrocyte function. Animals were exposed to drugs in liquid food before recording nephrocyte fluorescence intensity. The slit diaphragm architecture was investigated using immunofluorescence and subsequent automated quantification. Results: The genetically encoded tracer, combined with fast detection through enhanced widefield fluorescence microscopy, provided a faster but reliable screening assay for nephrocyte function compared with the established approach using FITC-albumin ex vivo . Rac1 is a key regulator of the actin cytoskeleton, involved in maintaining podocyte structure and function. In nephrocytes, overexpression of Rac1 resulted in mislocalization of slit diaphragm proteins and deeper membrane invaginations. Since nephrocyte function was further decreased as detected by the novel assay, we used this screening background relevant to podocyte biology for a pilot screen of 100 drugs. We identified significant improvement of nephrocyte function for zacopride, a respective agonist or antagonist of serotonin receptors, which restored the slit diaphragm architecture despite overexpression of Rac1 . The mechanism of action of zacopride appeared independent from the orthologs of the mammalian target proteins or direct Rac1 inhibition, suggesting a pleiotropic target. This hit from the pilot screen illustrates the potential of phenotypic drug screening to reveal unexpected therapeutic options. Conclusions: We present a proof of concept for whole-animal drug screening using podocyte-like Drosophila nephrocytes.